Abstract
Irofulven (6-Hydroxymethylacylfulvene, MGI-114) isthe first of a new class of anticancercompounds the acylfulvenes which arederived from the natural product, illudinS. Irofulven is a potent anticancer agentwith activity against a broad range ofhuman tumors in vitro and invivo. Irofulven covalently binds to DNA,inhibits DNA synthesis and inducesapoptosis. Clinical activity has beenobserved in phase I studies. Becausedisease stabilizations were observed inkidney cancer patients in the phase Itrials, we performed a phase II trial ofirofulven in this patient population.Twenty patients were accrued. Irofulven(11 milligrams per meter squared per day)was administered as a 5 minute intravenousinfusion for 5 consecutive days, andresponse was evaluated every 8 weeks.There were no objective responses. Themost common toxicities were nausea, emesis,and thrombocytopenia. Irofulven, at thedose and schedule administered in thistrial, showed no effect in metastatic renalcell cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Landis SH, Murray T, Bolden S, et al.: Cancer statistics, 1999. CA Cancer J Clin 49:8–31, 1999
Stadler WM, Vogelzang NJ: Low dose interleukin-2 in the treatment of metastatic renal cell carcinoma. Semin Oncol 22:67–73, 1995
Hawkins MJ: Immunotherapy with high-dose interleukin 2, in Vogelzang NJ, Scardino PT, Shipley WU, et al. (eds): Comprehensive textbook of genitourinary oncology. Baltimore, MD, Williams and Wilkins, pp 242–247, 1996
Minasian LM, Motzer RJ, Gluck L, et al.: Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368–1375, 1993
Negrier S, Escudier B, Lasset C, et al.: Recombinant human interleukin-2, recombinant human interferon alfa-2a or both in metastatic renal-cell carcinoma. N Engl J Med 338:1272–1278, 1998
McMorris TC, Kelner MJ, Wang W, et al.: Hydroxymethylacylfulvene (HMAF), an illudin derivative with superior antitumor properties. J Natl Prod 59(9):896–899, 1996
Woynarowski JM, Napier C, Koester SK, et al: Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI-114). Biochem Pharmacol 54:1181–1193, 1997
Herzig MCS, Arnett B, MacDonald JR et al.: Uptake and macromolecular binding of 6-hydroxymethylacylfulvene (HMAF, MGI-114) in a leukemia cell line, CEM (abstract) Proc Am Assoc Cancer Res 39:66, 1998
Kelner MJ, McMorris TC, Estes L, et al.: Efficacy of acylfulvene illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: Retention of activity against various mdr pheno-types and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. Cancer Res 55(21):4936–4940, 1995
MacDonald JR, Muscoplat CC, Dexter DL et al: Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 57(2): 279–283, 1997
Izbicka E, Lawrence R, Davidson K, et al.: Anticancer activity of MGI-114 against human tumor specimens taken directly from adult and pediatric patients (abstract 143), p. 37. Proceedings of the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1998
Kelner MJ, McMorris TC, Estes LA, et al.: Efficacy of MGI-114 in the myeloid leukemia HL60/MRI xenograft model (abstract). Proc Am Assoc Cancer Res 39:227, 1998
Mangold G, MacDonald J, Von Hoff D, et al: Antitumor activity of MGI-114 against two human prostate tumor xenograft models (abstract 142), p 37, Proceedings of the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1998
Kelner MJ, McMorris TC, Taetle R: HMAF (MGI-114) has antitumor activity in the mdrt/gp 170-positive human MV522 metastatic lung carcinoma xenograft (abstract). Proc Am Assoc Cancer Res 38:220, 1997
Eckhardt SG, Baker SD, Weiss GR, et al.: A phase I and pharmacokinetic (PK) study of the novel mushroom-derived cytotoxin, MGI-114 in patients with advanced cancer (abstract). Proc Am Soc Clin Oncol 17:233a, 1998
Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310–7313, 1988
Mangold G, MacDonald J, Von Hoff D, et al.: Enhanced antitumor activity of MGI-114 in combination with paclitaxel or topotecan against a human lung tumor xenograft model (abstract 141), p 37. Proceedings of the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, 1998
Barrera H, MacDonald J, Hilsenbeck S, et al.: In vitro antitumor activity of MGI-114 in combination with topotecan, taxol, cisplatin, etoposide, or gemcitabine against pediatric tumor cell lines (abstract). Proc Am Assoc Cancer Res 39:527 (#3588), 1998
Marty J, MacDonald J, Mangold G, et al.: Evidence of synergistic antitumor activity with MGI-114 in combination with irinotecan (ITN) or 5-fluorouracil (5-FU) against a human colon tumor xenograft model (abstract). Proc Am Assoc Cancer Res 39:527, 1998
Britten CD, Hilsenbeck SG, et al.: Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-FU in the HT29 human colon xenograft model. Cancer Res 59:1049, 1999
Kelner MJ, McMorris TC, et al.: Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan. Leukemia 14:136, 2000
Weitman S, Barrera H, et al.: MGI 114: Augmentation of antitumor activity when combined with topotecan. J Pediat Hematology/Oncology 22(4):306, 2000
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Amato, R.J., Perez, C. & Pagliaro, L. Irofulven, a Novel Inhibitor of DNA Synthesis, in Metastatic Renal Cell Cancer. Invest New Drugs 20, 413–417 (2002). https://doi.org/10.1023/A:1020649827173
Issue Date:
DOI: https://doi.org/10.1023/A:1020649827173